Abstract:
BioSante Pharmaceuticals, Inc. today announced that a comparative preclinical study demonstrated its calcium phosphate nanotechnology-based vaccine adjuvant, BioVant(TM), may be more effective than aluminum salt derivatives, the only adjuvant currently approved by the Food and Drug Administration. The study was conducted in collaboration with the U.S. Centers for Disease Control and Prevention in a previously unannounced BioSante collaboration.